Britain and America have finalized a key bilateral deal that will guarantee zero import taxes on UK drug shipments entering the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to raise funding on drugs through the NHS. This pledge ensures that tariffs on these key products will be held at zero for a duration of three years.
This development is in response to previous threats to dramatically increase tariffs on branded pharmaceutical products, with potential rates floated up to one hundred percent.
"This deal between the United Kingdom reinforces the global environment for innovative medicines and introduces much-needed balance to U.S.–U.K. drug exports," a release said.
Trade Impact
Pharmaceuticals constitute one of the Britain's largest exports to the America, which is by far the largest market for large UK drugmakers.
Trade data show that in the one-year period leading up to the third quarter, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This value accounted for nearly one-fifth of total UK exports in that period.
"This agreement safeguards employment, stimulates funding and paves the way for the UK to emerge as a worldwide center for life sciences," a minister remarked.
Specific NHS Changes
The deal includes several specific commitments from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to raise total public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must pay back to the NHS to stay within budget will be limited at 15%. Previously, refunds were more than twenty percent.
Broader Context
This agreement comes amid a long-running dispute between the sector and the British authorities over drug pricing and NHS adoption.
These tensions were exacerbated by arguments that American customers were paying several times more for the equivalent treatments than people in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been paused or scrapped, while substantial expansions have been pledged toward US facilities.
The Science Minister acknowledged that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a percentage of its resources over the last ten years.
